FNA · Paragon 28, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $62.34M | $61.02M | $61.08M | - | $52.78M | $51.01M | $52.04M | - | $46.01M |
| Cost of Revenue | - | $16.16M | $15.26M | $12.19M | - | $10.39M | $8.86M | $8.91M | - | $8.49M |
| Gross Profit | - | $46.18M | $45.76M | $48.90M | - | $42.39M | $42.15M | $43.13M | - | $37.52M |
| R&D | - | $5.66M | $7.08M | $7.58M | - | $7.24M | $7.68M | $7.05M | - | $6.34M |
| SG&A | - | $48.97M | $49.44M | $54.22M | - | $44.13M | $43.83M | $43.82M | - | $39.67M |
| Total Operating Expenses | - | $54.63M | $56.52M | $61.80M | - | $51.37M | $51.51M | $50.87M | - | $46.00M |
| D&A | - | - | - | $4.26M | - | - | - | $3.12M | - | - |
| Operating Income | - | ($8.45M) | ($10.77M) | ($12.90M) | - | ($8.98M) | ($9.36M) | ($7.74M) | - | ($8.49M) |
| Interest Expense | - | $3.03M | $2.92M | $2.62M | - | $1.12M | $803.0K | $1.21M | - | $1.09M |
| Income Tax | - | $205.0K | $230.0K | $224.0K | - | ($108.0K) | $269.0K | ($71.0K) | - | $201.0K |
| Net Income | - | ($12.34M) | ($13.78M) | ($15.23M) | - | ($8.33M) | ($10.90M) | ($9.05M) | - | ($9.72M) |
| EPS - Basic | - | ($0.15) | ($0.17) | ($0.18) | - | ($0.10) | ($0.13) | ($0.11) | - | ($0.13) |
| EPS - Diluted | - | ($0.15) | ($0.17) | ($0.18) | - | ($0.10) | ($0.13) | ($0.11) | - | ($0.13) |
Balance Sheet
| Line item | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $34.58M | $39.15M | $46.74M | $58.22M | $75.64M | $34.95M | $56.75M | $85.88M | $38.47M | $56.33M |
| Accounts Receivable | $39.02M | $35.82M | $36.71M | $40.26M | $37.32M | $33.62M | $34.33M | $37.26M | $37.69M | $35.96M |
| Inventory | $90.03M | $96.45M | $96.41M | $104.30M | $98.06M | $94.38M | $85.22M | $69.17M | $60.95M | $54.77M |
| Accounts Payable | $15.98M | $20.69M | $23.14M | $29.22M | $21.70M | $27.39M | $29.68M | $20.54M | $14.94M | $13.98M |
| Current Assets | $168.85M | $177.61M | $184.45M | $207.39M | $215.81M | $168.79M | $180.43M | $197.08M | $142.38M | $149.71M |
| Total Assets | $290.72M | $302.01M | $310.47M | $334.59M | $340.70M | $293.36M | $300.84M | $313.55M | $254.11M | $256.96M |
| Current Liabilities | $48.13M | $50.72M | $51.69M | $58.05M | $51.24M | $54.89M | $56.44M | $63.65M | $68.50M | $41.61M |
| Long-term Debt | $110.05M | $109.98M | $109.91M | $109.85M | $109.80M | $42.29M | $42.26M | $42.20M | $42.18M | $42.49M |
| Total Liabilities | $160.13M | $162.57M | $163.63M | $170.12M | $162.96M | $99.61M | $101.80M | $108.39M | $113.18M | $85.59M |
| Stockholders' Equity | $130.59M | $139.43M | $146.84M | $164.48M | $177.74M | $193.74M | $199.04M | $205.15M | $140.93M | $171.37M |
| Retained Earnings | ($178.28M) | ($167.16M) | ($154.83M) | ($130.86M) | ($115.63M) | ($96.07M) | ($87.74M) | ($76.84M) | ($67.79M) | ($29.03M) |
Cash Flow
| Line item | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | ($10.99M) | - | - | - | ($14.06M) | - | - |
| Investing Cash Flow | - | - | - | ($5.78M) | - | - | - | ($7.55M) | - | - |
| Financing Cash Flow | - | - | - | ($1.26M) | - | - | - | $69.37M | - | - |
| CapEx | - | - | - | - | - | - | - | $7.52M | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | ($21.58M) | - | - |
Ratios
| Metric | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | 74.1% | 75.0% | 80.0% | - | 80.3% | 82.6% | 82.9% | - | 81.5% |
| Operating margin | - | -13.6% | -17.6% | -21.1% | - | -17.0% | -18.3% | -14.9% | - | -18.5% |
| EBITDA margin | - | - | - | -14.2% | - | - | - | -8.9% | - | - |
| Net margin | - | -19.8% | -22.6% | -24.9% | - | -15.8% | -21.4% | -17.4% | - | -21.1% |
| Free cash flow margin | - | - | - | - | - | - | - | -41.5% | - | - |
| FCF / Net income | - | - | - | - | - | - | - | 2.38 | - | - |
| R&D / Revenue | - | 9.1% | 11.6% | 12.4% | - | 13.7% | 15.1% | 13.5% | - | 13.8% |
| SG&A / Revenue | - | 78.6% | 81.0% | 88.8% | - | 83.6% | 85.9% | 84.2% | - | 86.2% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | - | -4.1% | -4.4% | -4.6% | - | -2.8% | -3.6% | -2.9% | - | -3.8% |
| Return on equity | - | -8.8% | -9.4% | -9.3% | - | -4.3% | -5.5% | -4.4% | - | -5.7% |
| Return on invested capital | - | -2.7% | -3.3% | -3.7% | - | -3.0% | -3.1% | -2.5% | - | -3.1% |
| Liquidity | ||||||||||
| Current ratio | 3.51 | 3.50 | 3.57 | 3.57 | 4.21 | 3.07 | 3.20 | 3.10 | 2.08 | 3.60 |
| Quick ratio | 1.64 | 1.60 | 1.70 | 1.78 | 2.30 | 1.36 | 1.69 | 2.01 | 1.19 | 2.28 |
| Cash ratio | 0.72 | 0.77 | 0.90 | 1.00 | 1.48 | 0.64 | 1.01 | 1.35 | 0.56 | 1.35 |
| Leverage | ||||||||||
| Debt / Equity | 0.84 | 0.79 | 0.75 | 0.67 | 0.62 | 0.22 | 0.21 | 0.21 | 0.30 | 0.25 |
| Debt / Assets | 0.38 | 0.36 | 0.35 | 0.33 | 0.32 | 0.14 | 0.14 | 0.13 | 0.17 | 0.17 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | -2.8x | -3.7x | -4.9x | - | -8.0x | -11.7x | -6.4x | - | -7.8x |
| Equity multiplier | 2.23 | 2.17 | 2.11 | 2.03 | 1.92 | 1.51 | 1.51 | 1.53 | 1.80 | 1.50 |
| Liabilities / Assets | 0.55 | 0.54 | 0.53 | 0.51 | 0.48 | 0.34 | 0.34 | 0.35 | 0.45 | 0.33 |
| Efficiency | ||||||||||
| Asset turnover | - | 0.21 | 0.20 | 0.18 | - | 0.18 | 0.17 | 0.17 | - | 0.18 |
| Inventory turnover | - | 0.17 | 0.16 | 0.12 | - | 0.11 | 0.10 | 0.13 | - | 0.16 |
| Days sales outstanding | - | 210d | 220d | 241d | - | 232d | 246d | 261d | - | 285d |
| Days inventory outstanding | - | 2179d | 2306d | 3124d | - | 3314d | 3512d | 2835d | - | 2354d |
| Days payable outstanding | - | 467d | 553d | 875d | - | 962d | 1223d | 842d | - | 601d |
| Cash conversion cycle | - | 1921d | 1972d | 2489d | - | 2585d | 2534d | 2255d | - | 2039d |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | 18.1% | 19.6% | 17.4% | - | 14.7% | 20.0% | 57.2% | - | 28.3% |
| Revenue CAGR (3y) | - | 20.2% | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | 8.9% | 8.6% | 13.4% | - | 13.0% | 20.9% | 61.8% | - | 30.5% |
| Operating income growth (YoY) | - | 5.9% | -15.0% | -66.7% | - | -5.8% | -3.1% | 8.3% | - | - |
| Net income growth (YoY) | - | -48.1% | -26.5% | -68.3% | - | 14.3% | -478.5% | -1617.6% | - | - |
| EPS growth (YoY) | - | -50.0% | -30.8% | -63.6% | - | 23.1% | -160.0% | 8.3% | - | -8.3% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -26.5% | -28.0% | -26.2% | -19.8% | 26.1% | 13.1% | 12.5% | 578.1% | -26.7% | 602.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Business segments
$256.18M totalSingle Reportable Segment$256.18M · 100.0%
Geographic
$256.18M totalUS$212.15M · 82.8%
Non Us$44.04M · 17.2%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing Paragon 28 against the 5 most active filers in the same SIC group.